Small-Cap Momentum Watch: Upcoming Catalysts for October 5–9
10/4/20268 min read
From operational updates to conference participation, we’ve highlighted the small-cap events that could drive attention this week.
--
Companies with Material Events This Week:
● BESS – Co-CEO Bob Brilon will present twice at the MoneyShow Conference in Orlando, Florida, being held October 5–7, 2026. Presentations are scheduled for October 5 from 3:25–3:55 p.m. ET and October 6 from 2:55–3:40 p.m. ET, with management also meeting investors and highlighting the company’s NYSE American uplisting, recent Q2 2026 revenue and profitability, and strategic initiatives.
● MIRA – Will present Ketamir-2 at the International Conference on Addiction and Psychiatry in Tokyo from October 5–6, 2026. Chief Scientific Advisor Dr. Itzchak Angel will deliver an oral presentation covering Phase 1 safety, pharmacokinetics, and clinical development of the oral selective NMDA modulator for chemotherapy-induced peripheral neuropathy.
● XOS – Will participate in the APTA TRANSform Conference & EXPO in Chicago from October 4–7, 2026, showcasing the Xos Hub mobile energy-storage and EV-charging system for public and commercial fleet electrification.
● GANX – Will present long-term open-label extension data from the Phase 1b rexaceract study at the International Congress of Parkinson’s Disease and Movement Disorders in Seoul, being held October 4–8, 2026. The poster reports stabilization of MDS-UPDRS scores over 360 days of dosing.
● TELO – Will participate in the 3rd International Conference on Women’s Health and Breast Cancer in Tokyo from October 5–6, 2026.
● SAFX – Will hold its postponed virtual special meeting of stockholders on October 5, 2026 at 11:00 a.m. ET regarding the proposed business combination with DevvStream and Southern Energy. Shareholders will vote on the transaction-related stock issuance, an increase in authorized Class A shares from 500 million to 1.7 billion, election of seven directors, expansion of the equity incentive plan, and a possible adjournment.
● CGEN – Will host a virtual KOL event on October 5, 2026 at 8:00 a.m. ET focused on COM701 and the ovarian cancer treatment landscape. The event will preview the randomized MAIA-ovarian adaptive platform trial design, discuss the expected Q1 2027 interim median progression-free survival analysis, and include an update on the Unigen AI/ML-powered target-discovery platform.
● NUWE – Will participate in the Pediatric Paracorporeal and Extracorporeal Therapies Summit at Texas Children’s Hospital in Houston from October 6–8, 2026, focused on pediatric CRRT, ECMO, and extracorporeal support technologies.
● ERNA – CEO Sanjeev Luther will deliver an Innovation Spotlight presentation at the 2026 Cell & Gene Meeting on the Mesa on October 6, 2026 at 1:30 p.m. The presentation will highlight its off-the-shelf iMSC platform, lead candidate ERNA-101, and plans to establish proof of concept initially in platinum-resistant ovarian cancer.
● SXTP – Will disclose interim results from its clinical study of tafenoquine in patients hospitalized with severe babesiosis on October 6, 2026. The company will also host a KOL investor webinar the same day to review the data, unmet need in relapsing and treatment-refractory babesiosis, and the potential role of tafenoquine.
● ICU – Chief Medical Officer Kevin Chung will deliver an invited talk at the PPETS conference in Houston from October 6–8, 2026, where specialists will discuss pediatric continuous renal replacement therapy, ECMO, and related extracorporeal therapies.
● QTI – Will be recognized during Premier’s Supplier Innovation Celebration at the 2026 Breakthroughs Conference and Exhibition, taking place October 6–8, 2026. The event highlights healthcare technologies selected for their potential impact on patient care.
● SLMT – Management will participate in a live panel at Solana Capital Forum Singapore on October 6, 2026 during TOKEN2049 week. The discussion will focus on public-market financing of Solana ecosystem companies, treasury strategies, institutional participation, and long-term capital formation.
● ROLR – CEO Seth Young will participate in the PREDICT 2026 prediction-markets conference in New York on October 6–7, 2026. He will join the “Future of Interactive Gaming: Innovation, Technology & Scale” panel on October 6 from 2:15–2:55 p.m. ET.
● CLLS – Will participate in Barclays’ Fall Focus Biotech 1x1 Day in New York on October 6, 2026.
● FEAM – Will host a special shareholder conference call on October 6, 2026 at 4:30 p.m. ET to discuss its completed acquisition of Searles Valley Minerals and operating plans for the acquired assets. The transaction moves the company from a pre-revenue developer to a revenue-generating producer of boron and other critical industrial minerals.
● TOYO – Will webcast its 2026 Analyst Day on October 6, 2026, with management expected to discuss strategy, market trends, and expansion plans.
● LFCR – Will participate in the CPHI Global Conference in Milan from October 6–8, 2026. Commercial leadership will meet prospective customers to discuss process-development and manufacturing services for injectable programs.
● RCKT – Will host a virtual investor webinar on October 6, 2026 at 4:30 p.m. ET to provide a comprehensive update on the Danon disease program following FDA alignment on continued enrollment and dosing and key elements of the pivotal Phase 2 RP-A501 study, including the recalibrated dose, 12-patient pivotal population, and 12-month co-primary endpoints.
● OABI – Will hold an Investor & Analyst Day on October 6, 2026 at 8:00 a.m. PT / 11:00 a.m. ET in Emeryville, California. Management will provide corporate and technology updates, discuss select partner programs and the xPloration platform, and host Q&A, laboratory tours, and technology demonstrations for in-person attendees.
● RZLV – Will host an Investor Day at Nasdaq MarketSite in New York on October 6, 2026 focused on its agentic-commerce business and expanding AI-infrastructure capabilities.
● DAIC – Is targeting October 6, 2026 for closing of its acquisition of Envoy Technologies under a definitive September 25 purchase agreement. The transaction values the Envoy-side consideration at $65 million based on a $6.00 reference price and contemplates 10,833,333 shares and preferred-stock equivalents, subject to customary closing conditions, required Israeli and Tel Aviv Stock Exchange approvals, and conversion of Envoy’s $12.5 million convertible note.
● AIDX – Will host an investor webinar on October 7, 2026 at 12:00 p.m. ET. CEO Jonathan Cohen will discuss the September 23 FDA advisory-panel meeting relevant to multi-cancer early detection, the company’s OneTest franchise model, laboratory interest, and new state funding initiatives for firefighter cancer screening.
● AUUD – Will reconvene its adjourned Special Meeting of Stockholders on October 7, 2026 at 11:30 a.m. ET regarding the proposed merger with Thramann Holdings. The merger requires approval from a majority of all outstanding shares, and the adjournment was intended to provide additional time for stockholders to vote.
● LGVN – Will participate virtually in the Abundance Longevity Trip from October 7–11, 2026.
● MVIS – Will host a video-enabled business update on October 7, 2026 at 4:00 p.m. ET. CEO Glen DeVos, CFO Christine Chambers, and Chief Commercial Officer James Byun will discuss commercial progress, revenue and operating-expense expectations, and the business outlook.
● STEX – CEO Henry McPhie will attend Digital Asset Summit Asia in Singapore on October 7, 2026 and TOKEN2049 from October 7–8, meeting institutional investors and prospective partners.
● SUIG – Will serve as a Platinum sponsor of Sui Basecamp 2026 at Marina Bay Sands in Singapore from October 7–8, 2026. The event will focus on the Sui ecosystem and the emerging agentic economy, including trust, identity, payments, autonomous agents, and verifiable execution.
● LXEO – Will deliver an oral presentation on LX2006 at the International Congress of Parkinson’s Disease and Movement Disorders in Seoul on October 7, 2026 at 12:30 p.m. KST. The presentation will provide early neurologic assessments from two Phase 1/2 studies in Friedreich ataxia, including new mFARS subscore analyses.
● CTSO – Will have CytoSorb-related data presented in open-heart surgery at the European Association for Cardio-Thoracic Surgery Annual Meeting in Barcelona from October 7–10, 2026.
● DGNX – Will hold an Extraordinary General Meeting virtually on October 8, 2026 at 10:00 a.m. ET. Shareholders will vote on the proposed Resulticks acquisition, issuance of 600 million consideration shares, the related change of control, an increase in authorized shares to 1.3 billion ordinary shares, a 1-for-10 share consolidation, amended governing documents, an expanded equity incentive plan, and ancillary transaction issuances.
● AENT – Will participate in New York Comic Con from October 8–11, 2026 at the Jacob K. Javits Convention Center, selling 16 limited-edition exclusives through its popmarket booth across collectibles, music merchandise, games, and related licensed products.
● SFIX – Management will participate in the 2026 Global Consumer & Retail Conference in New York on October 8, 2026, with a fireside chat scheduled for 10:55 a.m. ET.
● LOAN – October 8, 2026 is the record date for its previously declared $0.11 per-share cash dividend, which is scheduled to be paid October 15.
● OCGN – Will present 12-month topline Phase 2 ArMaDa safety and efficacy results for OCU410 in geographic atrophy at the American Academy of Ophthalmology Annual Meeting in New Orleans on October 9, 2026 from 5:05–5:10 p.m. CT. Additional OCU410, OCU410ST, and OCU400 presentations continue through October 12.
● JAGX – Napo Pharmaceuticals will present preliminary results from an ongoing open-label study of crofelemer in adults with short bowel syndrome with intestinal failure at the American College of Gastroenterology Annual Scientific Meeting in Nashville, which begins October 9, 2026.
● NCEL – Senior management will attend the Breakthrough T1D Clinical & Research Congress in Philadelphia from October 9–11, 2026, meeting with researchers, clinicians, investors, and potential partners regarding NCEL-101 and preparations for a planned Phase 1/2a trial in type 1 diabetes.
● CVRX – Barostim will be featured across eight scientific presentations at the Heart Failure Society of America Annual Scientific Meeting in Phoenix from October 9–12, 2026, including late-breaking clinical data, podium sessions, posters, and information related to the BENEFIT-HF trial.
● VRCA – Will present posters at the Fall Clinical Dermatology Conference in Las Vegas from October 8–11, 2026 covering a new analysis of Phase 3 YCANTH data and an encore presentation of Phase 2 VP-315 findings.
● SABS – Will present encore Phase 1 SAB-142 data at the inaugural Breakthrough T1D Clinical & Research Congress in Philadelphia from October 9–11, 2026. Presentations will include available safety and efficacy data and information on the SAFEGUARD and PRISE-hATG studies.
● IPSC – Will present on CNTY-813, its iPSC-derived islet replacement therapy engineered with Allo-Evasion 5.0, at the Breakthrough T1D Clinical & Research Congress in Philadelphia from October 9–11, 2026.
--
Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTimePenny is not a fiduciary by virtue of any person's use of or access to this content. We were NOT compensated for this article.
Disclaimer: Penny stock trading involves substantial risk, so always research every alert before trading, consult with a licensed professional before trading, only invest what you can afford to lose, and always trade with caution. Readers should independently investigate and fully understand all risks before investing. Results listed are NOT typical and individual results may and most likely will vary. Bigtimepennystocks.com and its staff are NOT licensed investment advisors or broker/dealers of any kind.Alerts are not a solicitation or recommendation to buy/sell/hold securities but merely investment ideas that should NEVER serve as the basis of your trading decisions. Bigtimepennystocks.com and its newsletter are for entertainment purposes only. This website and its reports are for general information purposes as we are engaged in the business of marketing and advertising companies for monetary compensation. Any investment decision should be discussed with a financial adviser before taking place. Please invest carefully and read investment information available at the website of the SEC at http://www.sec.gov.
Subscribe to our Free Newsletter
Copyright © 2023 BigTimePennyStocks.com - All Rights Reserved.